Aldeyra Shifts Focus to Commercialization, With Upcoming FDA Decision on Reproxalap a Potential Catalyst
-
Aldeyra's 52% reduction in R&D spending signals a shift from drug development to commercialization readiness, with the upcoming PDUFA decision for reproxalap as a potential catalyst.
-
With $151.7M cash on hand and an estimated 40-month runway, Aldeyra has financial stability despite market cap shrinkage to $382.63M.
-
Approaching FDA milestones like the November PDUFA date for reproxalap in dry eye disease represent pivotal catalysts for Aldeyra.
-
Reproxalap's first-in-class RASP inhibition mechanism gives it a unique edge in multi-billion dollar dry eye and allergic conjunctivitis markets.
-
Despite risks like regulatory uncertainty and competition, Aldeyra remains a "Buy" for long-term investors, with significant upside if reproxalap gains approval.
